From cardio-oncology to cardio-onco-pharmacology: Towards a multidisciplinary approach in the understanding and management of cardiotoxicity.

Autor:	Ederhy S; Department of Cardiology, AP-HP, Saint Antoine Hospital, UNICO Cardio-oncology program, GRC n(o) 27, 184, rue du faubourg saint Antoine, 75012 Paris, France. Electronic address: stephane.ederhy@aphp.fr., Devos P; Department of Cardiology, AP-HP, Pitié-Salpétrière Hospital, UNICO Cardio-oncology program, 75012 Paris, France., Cohen A; Department of Cardiology, AP-HP, Saint Antoine Hospital, UNICO Cardio-oncology program, GRC n(o) 27, 184, rue du faubourg saint Antoine, 75012 Paris, France., Pinna B; INSERM, CIC-1901, Sorbonne Université, AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, UNICO Cardio-oncology program, 75013 Paris, France., Bretagne M; INSERM, CIC-1901, Sorbonne Université, AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, UNICO Cardio-oncology program, 75013 Paris, France., Nguyen LS; Research & Innovation of CMC Ambroise Paré, 92200 Neuilly-sur-Seine, France., Salem JE; INSERM, CIC-1901, Sorbonne Université, AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, UNICO Cardio-oncology program, 75013 Paris, France; Research & Innovation of CMC Ambroise Paré, 92200 Neuilly-sur-Seine, France.
Jazyk:	angličtina
Zdroj:	Therapie [Therapie] 2022 Mar-Apr; Vol. 77 (2), pp. 197-206. Date of Electronic Publication: 2021 Nov 25.
DOI:	10.1016/j.therap.2021.09.008
Abstrakt:	Cardio-oncology is an emerging field that transformed the medical management of patients with cancer. It encompasses the prevention and treatment of cardiovascular toxicities related to cancer treatments, aiming to reduce cardiac adverse events among cancer survivors. Cardiovascular toxicities related to cancer treatments are described through data collected during phase I to phase III therapeutic trials, and post-marketing surveillance (phase IV). Pharmacovigilance analyses, based on datamining from these extensive databases, allowed to understanding and identifying new adverse drug reactions, some recently made available, such as immunotherapy or inhibitor of Bruton tyrosine kinase (IBTK). (Copyright © 2021 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu